Immunogenicity of anti-HLA antibodies in pancreas and islet transplantation

Chaigne, Benjamin; Geneugelijk, Kirsten; Bedat, Benoît; Ahmed, Mohamed Alibashe; Hönger, Gideon; De Seigneux Matthey, Sophie; Demuylder-Mischler, Sandrine; Berney, Thierry; Spierings, Eric; Ferrari-Lacraz, Sylvie; Villard, Jean

doi:10.3727/096368916X691673

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Immunogenicity of anti-HLA antibodies in pancreas and islet transplantation
Authors		Chaigne, Benjamin Geneugelijk, Kirsten Bedat, Benoît Ahmed, Mohamed Alibashe Hönger, Gideon De Seigneux Matthey, Sophie Demuylder-Mischler, Sandrine Berney, Thierry Spierings, Eric Ferrari-Lacraz, Sylvie Villard, Jean show all authors [1 - 11]
Published in		Cell transplantation. 2016, vol. 25, p. 2041-2050
Abstract		The aim of the current study was to characterize the anti-HLA antibodies before and after pancreatic islet or pancreas transplantation. We assessed the risk of anti-donor specific antibody (DSA) sensitization in a single-center, retrospective clinical study at Geneva University Hospital. Data regarding clinical characteristics, graft outcome, HLA mismatch, donor HLA immunogenicity and anti-HLA antibody characteristic were collected. Between January 2008 and July 2014, 18 patients received islet transplants and 26 patients received a pancreas transplant. Eleven out of 18 patients (61.1%) in the islet group and 12 out of 26 patients (46.2%) in the pancreas group had anti-HLA antibodies. Six patients (33.3%) developed DSA against HLA of the islets and 10 patients (38.4%) developed DSA against HLA of the pancreas. Most of the DSA were at low level. Several parameters such as gender, number of transplantation, HLA mismatch, eplet mismatch and PIRCHE-II numbers, rejection and infection were analyzed. Only the number of PIRCHE-II was associated with the development of anti-HLA class II de novo DSA. Overall, the development of de novo DSA did not influence graft survival as estimated by insulin independence. Our results indicated that pre-transplant DSA at low levels, do not restrict islet or pancreas transplantation, especially islets transplantation (27.8% versus 15.4.%). de novo DSA do occur at a similar rate in both pancreas and islet transplant recipients mainly of class II and the immunogenicity of donor HLA is a parameter that should be taken into consideration. Low level DSA combined with an adequate immunosuppressive regimen and a close follow-up is acceptable in both pancreas and islet transplantation and are not associated with reduced graft survival or graft function.
Identifiers		DOI: 10.3727/096368916X691673 PMID: 27196533
Full text		Article (Published version) (438 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département de chirurgie
Research groups		Insuffisance rénale chronique (941) La transplantation d'îlots de Langerhans (623) Transplantation immunologie et osteoimmunologie (561)
Citation (ISO format)		CHAIGNE, Benjamin et al. Immunogenicity of anti-HLA antibodies in pancreas and islet transplantation. In: Cell transplantation, 2016, vol. 25, p. 2041-2050. doi: 10.3727/096368916X691673 https://archive-ouverte.unige.ch/unige:89616